Patents by Inventor Elizabeth Grimm
Elizabeth Grimm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7109179Abstract: The present invention relates to the use of tumor suppressor genes in combination with a DNA damaging agent or factor for use in killing cells, and in particular cancerous cells. A tumor suppressor gene, p53, was delivered via a recombinant adenovirus-mediated gene transfer both in vitro and in vivo, in combination with a chemotherapeutic agent. Treated cells underwent apoptosis with specific DNA fragmentation. Direct injection of the p53-adenovirus construct into tumors subcutaneously, followed by intraperitoneal administration of a DNA damaging agent, cisplatin, induced massive apoptotic destruction of the tumors. The invention also provides for the clinical application of a regimen combining gene replacement using replication-deficient wild-type p53 adenovirus and DNA-damaging drugs for treatment of human cancer.Type: GrantFiled: February 23, 2004Date of Patent: September 19, 2006Assignee: Board of Regents, the University of Texas SystemInventors: Jack A. Roth, Toshiyoshi Fujiwara, Elizabeth A. Grimm, Tapas Mukhopadhyay, Wei-Wei Zhang, Laurie B. Owen-Schaub
-
Publication number: 20060182718Abstract: The present invention relates to the use of tumor suppressor genes in combination with a DNA damaging agent or factor for use in killing cells, and in particular cancerous cells. A tumor suppressor gene, p53, was delivered via a recombinant adenovirus-mediated gene transfer both in vitro and in vivo, in combination with a chemotherapeutic agent. Treated cells underwent apoptosis with specific DNA fragmentation. Direct injection of the p53-adenovirus construct into tumors subcutaneously, followed by intraperitoneal administration of a DNA damaging agent, cisplatin, induced massive apoptotic destruction of the tumors. The invention also provides for the clinical application of a regimen combining gene replacement using replication-deficient wild-type p53 adenovirus and DNA-damaging drugs for treatment of human cancer.Type: ApplicationFiled: February 6, 2006Publication date: August 17, 2006Inventors: Jack Roth, Toshiyoshi Fujiwara, Elizabeth Grimm, Tapas Mukhopadhyay, Wei-Wei Zhang, Laurie Owen-Schaub
-
Publication number: 20060134801Abstract: The present invention relates to compositions and methods involving MDA-7. More specifically, the present invention is directed to diagnostic, prognostic, and therapeutic treatment compositions and methods for treatment of cancer and other angiogenesis-related disorders (anti-angiogenesis therapy). The present invention is also directed to methods of purification of MDA-7.Type: ApplicationFiled: March 2, 2004Publication date: June 22, 2006Inventors: Sunil Chada, John Mumm, Rajagopal Ramesh, Abner Mhashilkar, Raymond Meyn, Elizabeth Grimm
-
Publication number: 20050089511Abstract: The present invention relates to the use of tumor suppressor genes in combination with a DNA damaging agent or factor for use in killing cells, and in particular cancerous cells. A tumor suppressor gene, p53, was delivered via a recombinant adenovirus-mediated gene transfer both in vitro and in vivo, in combination with a chemotherapeutic agent. Treated cells underwent apoptosis with specific DNA fragmentation. Direct injection of the p53-adenovirus construct into tumors subcutaneously, followed by intraperitoneal administration of a DNA damaging agent, cisplatin, induced massive apoptotic destruction of the tumors. The invention also provides for the clinical application of a regimen combining gene replacement using replication-deficient wild-type p53 adenovirus and DNA-damaging drugs for treatment of human cancer.Type: ApplicationFiled: February 23, 2004Publication date: April 28, 2005Inventors: Jack Roth, Toshiyoshi Fujiwara, Elizabeth Grimm, Tapas Mukhopadhyay, Wei-Wei Zhang, Laurie Owen-Schaub
-
Patent number: 6797702Abstract: The present invention relates to the use of tumor suppressor genes in combination with a DNA damaging agent or factor for use in killing cells, and in particular cancerous cells. A tumor suppressor gene, p53, was delivered via a recombinant adenovirus-mediated gene transfer both in vitro and in vivo, in combination with a chemotherapeutic agent. Treated cells underwent apoptosis with specific DNA fragmentation. Direct injection of the p53-adenovirus construct into tumors subcutaneously, followed by intraperitoneal administration of a DNA damaging agent, cisplatin, induced massive apoptotic destruction of the tumors. The invention also provides for the clinical application of a regimen combining gene replacement using replication-deficient wild-type p53 adenovirus and DNA-damaging drugs for treatment of human cancer.Type: GrantFiled: August 26, 1997Date of Patent: September 28, 2004Assignee: Board of Regents, The University of Texas SystemInventors: Jack A. Roth, Toshiyoshi Fujiwara, Elizabeth A. Grimm, Tapas Mukhopadhyay, Wei-Wei Zhang, Laurie B. Owen-Schaub
-
Publication number: 20020183271Abstract: The present invention relates to gene therapy methods for the treatment of human disease. More specifically, the invention is directed to methods for treating a subject with an angiogenesis-related disease. In one embodiment, an adenoviral expression construct comprising a nucleic acid encoding a human MDA-7 protein under the control of a promoter operable in eukaryotic cells, is administered to said patient with an angiogenesis-related disease. The present invention thus provides for treatment of angiogenesis-related disease by through expression of mda-7 and inhibition angiogenesis. Such diseases include cancer.Type: ApplicationFiled: December 7, 2001Publication date: December 5, 2002Inventors: Sunil Chada, Elizabeth Grimm, Abner Mhashilkar, Rajagopal Ramesh
-
Patent number: 6069134Abstract: The present invention relates to the use of tumor suppressor genes in combination with a DNA damaging agent or factor for use in killing cells, and in particular cancerous cells. A tumor suppressor gene, p53, was delivered via a recombinant adenovirus-mediated gene transfer both in vitro and in vivo, in combination with a chemotherapeutic agent. Treated cells underwent apoptosis with specific DNA fragmentation. Direct injection of the p53-adenovirus construct into tumors subcutaneously, followed by intraperitoneal administration of a DNA damaging agent, cisplatin, induced massive apoptotic destruction of the tumors. The invention also provides for the clinical application of a regimen combining gene replacement using replication-deficient wild-type p53 adenovirus and DNA-damaging drugs for treatment of human cancer.Type: GrantFiled: October 17, 1997Date of Patent: May 30, 2000Assignee: Board of Regents, The University of Texas SystemInventors: Jack A. Roth, Toshiyoshi Fujiwara, Elizabeth A. Grimm, Tapas Mukhopadhyay, Wei-Wei Zhang, Laurie B. Owen-Schaub
-
Patent number: 5747469Abstract: The present invention relates to the use of tumor suppressor genes in combination with a DNA damaging agent or factor for use in killing cells, and in particular cancerous cells. A tumor suppressor gene, p53, was delivered via a recombinant adenovirus-mediated gene transfer both in vitro and in vivo, in combination with a chemotherapeutic agent. Treated cells underwent apoptosis with specific DNA fragmentation. Direct injection of the p53-adenovirus construct into tumors subcutaneously, followed by intraperitoneal administration of a DNA damaging agent, cisplatin, induced massive apoptotic destruction of the tumors. The invention also provides for the clinical application of a regimen combining gene replacement using replication-deficient wild-type p53 adenovirus and DNA-damaging drugs for treatment of human cancer.Type: GrantFiled: April 25, 1994Date of Patent: May 5, 1998Assignee: Board of Regents, The University of Texas SystemInventors: Jack A. Roth, Toshiyoshi Fujiwara, Elizabeth A. Grimm, Tapas Mukhopadhyay, Wei-Wei Zhang, Laurie B. Owen-Schaub
-
Patent number: 5229109Abstract: The properties of two recombinant human IL-2 analogues with mutations at Arginine 38 (.fwdarw.Alanine) and Phenylalanine 42 (.fwdarw.Lysine) were analyzed and compared to those of native IL-2. These analogues were found to maintain their ability to bind to the intermediate IL-2 receptor, p75, while binding only minimally to the high affinity p55+p75 receptor complex. The analogues also maintained the ability to stimulate peripheral blood mononuclear cells to generate lymphokine activated killing (LAK). However, IL-1.beta. and TNF-.alpha. secretion were significantly reduced in response to the analogues, as compared to the native IL-2 molecule. These analogues are therefore potentially valuable low-toxicity alternatives to IL-2 in human immunotherapy and adoptive immunotherapy treatment strategies.Type: GrantFiled: April 14, 1992Date of Patent: July 20, 1993Assignee: Board of Regents, The University of Texas SystemInventors: Elizabeth A. Grimm, Keith Heaton